Crinetics Pharmaceuticals Stock Surges Nearly 100% After Acquisition by Vertex Pharmaceuticals
Shares of Crinetics Pharmaceuticals surged nearly 98% this week after it announced a $10 billion all-cash acquisition deal with Vertex Pharmaceuticals. The pharmaceutical company, which recently had its first FDA-approved drug in September 2025, is being acquired to diversify Vertex's portfolio beyond cystic fibrosis into rare diseases.
